Therapeutic Solutions International Granted Patent on Commercially Available QuadraMune® Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients

Stock Information for Chemesis International

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Chemesis International

Therapeutic Solutions International to Voluntarily Delist
Therapeutic Solutions International Receives Notice of Allowance for Landmark Patent Covering Cellular Therapy of Lung Diseases
Immunology Based Suicide Prevention Company Campbell Neurosciences Announces Appointment of Public Company Veteran Raymond Oliver as Chairman of the Board
Therapeutic Solutions International Announces Landmark Finding Regarding Mechanism of Action of its JadiCell Stem Cell Product
Therapeutic Solutions International Files Patent on "Facilitating Effects" of JadiCells on Gene Therapy Mediated Cell Differentiation
Therapeutic Solutions International Files Lawsuit in San Diego Superior Court to Obtain Identities of Certain Individuals or Entities
Therapeutic Solutions International Launches Adult Stem Cell Therapy Company Focused on Curing Epilepsy
Therapeutic Solutions International Subsidiary Immunotherapy Company Res Nova Bio, Inc. Announces Positive Data on First Four Advanced Cancer Patients Treated with FloraStilbene(TM)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.